BILE DUCT CANCER MARKET ANALYSIS

Bile Duct Cancer Market, By Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, 5 fluorouracil (5-FU)), Targeted Therapy ( Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy (Pembrolizumab (Phase 3)), Others) , By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In February 2023, AstraZeneca, a global biopharmaceutical company, had received approval from the Central Drugs Standard Control Organisation (CDSCO) to introduce Durvalumab for treating biliary tract cancer (BTC) in India. BTC encompasses a set of uncommon and aggressive gastrointestinal (GI) cancers originating from the cells of the bile ducts (cholangiocarcinoma), gallbladder, or ampulla of Vater (junction of the bile and pancreatic ducts with the small intestine).
In July 2021, Pemigatinib (Pemazyre) was approved by the National Institute of Health and Care Excellence (NICE) for patients with a rare form of bile duct cancer known as FGFR2-positive cholangiocarcinoma, which has advanced or spread following initial chemotherapy. Kruti Shrotri of Cancer Research U.K. praises the decision, emphasizing its significance in broadening treatment possibilities for patients grappling with the rarity and treatment resistance of their cancer.

Bile Duct Cancer Market Report Snapshots